IMI impact on dementia - Event
Start Date 15/06/2021About this event
IMI has over 20 projects in this area accounting for around 10 % of IMI’s budget. Most focus on Alzheimer’s disease, the most prevalent cause of dementia, but we also have projects on other dementia causing conditions such as Parkinson’s and Huntington’s disease. The projects cover the whole spectrum of medical research and drug development, and patients play an active role in many projects, bringing their knowledge and experience of their disease to the table. Given the complexity of the brain and nervous system, it is unsurprising that many of our projects are unravelling the role of specific genes and proteins in disease. Other projects are exploring ways of identifying people at greatest risk of developing dementia and on how to improve diagnosis, management and development of novel treatments. We also have projects applying a ‘big data’ approach to progress in the area.
This event was part of a series of live sessions that IMI is organising on IMI Impacts, where key actors explored the key challenges in their respective fields and demonstrate how IMI contributed. During these sessions, we also shared patients’ testimonies, as they are the ultimate beneficiaries of IMI’s funded research.
Furthermore, we engaged IMI stakeholders in a broader discussion on IMI’s impact. With this initiative, we demonstrated the successful IMI model of radical collaboration.
Find out more about...
IMI impact on dementia
Outline of the event and presentations
Welcome and introduction by Elisabetta Vaudano, Principal Scientific Manager, IMI |
|
The challenge, the vision and the value by Luc Truyen, Global Head- Development and External Affairs-Neuroscience, Janssen Pharmaceutical Companies of Johnson & Johnson Presentation Recording Helen Rochford-Brennan, Member and past Chair, Alzheimer Europe European Working Group of People with Dementia Recording |
|
How IMI projects have addressed the challenge & 'moved the needle' , Solutions from IMI projects by Carlos Diaz, CEO, SYNAPSE Research Management Partners. S.L, NEURONET Presentation Recording Rachel Steeg, Fraunhofer UK Research Ltd, EBISC2 Presentation Recording Gill Farrar, Global Medical Leader, GE Healthcare Medical Affairs, AMYPAD Presentation Recording |
|
Q&A Time Recording
|
|
Closing remarks Recording by Professor Olivier Blin, Head of the Clinical Pharmacology & Pharmacovigilance Department, Aix-Marseille University, Member of IMI Scientific Committee Elisabetta Vaudano, Principal Scientific Manager, IMI |
Meet the speakers
Luc Truyen Global Head- Development and External Affairs-Neuroscience Janssen Pharmaceutical Companies of Johnson & Johnson |
Helen Rochford-Brennan Member and past Chair Alzheimer Europe European Working Group of People with Dementia |
Carlos Diaz CEO SYNAPSE Research Management Partners. S.L |
Rachel Steeg Project Manager Fraunhofer UK Research Ltd |
Gill Farrar Global Medical Leader GE Healthcare Medical Affairs |
Professor Olivier Blin Head of the Clinical Pharmacology & Pharmacovigilance Department Aix-Marseille University Member of IMI Scientific Committee |
Moderated by:
|
Elisabetta Vaudano Principal Scientific Manager, IMI |